

Resource Summary Report

Generated by RRID on Sep 6, 2026

PE anti-human/mouse Granzyme B Recombinant

RRID:AB_2687032

Type: Antibody

Proper Citation

BioLegend Cat# 372208, RRID:AB_2687032

Antibody Information

URL: http://antibodyregistry.org/AB_2687032

Proper Citation: BioLegend Cat# 372208, RRID:AB_2687032

Target Antigen: Granzyme B

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: PE anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA16A02

Antibody ID: AB_2687032

Vendor: BioLegend

Catalog Number: 372208

Alternative Catalog Numbers: 372207

Record Creation Time: 20231110T034045+0000

Record Last Update: 20260829T204231+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human/mouse Granzyme B Recombinant.

No alerts have been found for PE anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. Cell reports, 45(5), 117324.

Lei G, et al. (2026) Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell.

Wang Y, et al. (2026) Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4+ T cell help. Cell reports methods, 101533.

Li A, et al. (2026) 5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation. Cell reports. Medicine, 102537.

Wang Y, et al. (2026) Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC class I-deficient solid tumors. Cell reports, 45(3), 117035.

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. Cell reports. Medicine, 7(3), 102659.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. Cell reports. Medicine, 7(4), 102706.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. Molecular cell.

Menezes-Silva L, et al. (2026) Hormonal rewiring of immunity during dietary restriction ensures host defense and systemic glucose conservation. Immunity, 59(3), 700.

Shen J, et al. (2026) Kr??ppel-like factors 2 and 3 regulate T cell exhaustion by directing T cell residency and migration. Immunity, 59(5), 1287.

Fan AE, et al. (2025) STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition. Molecular cancer therapeutics, 24(3), 419.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Xiao Y, et al. (2025) HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. *Cell metabolism*.

Niu Y, et al. (2025) TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity. *Journal of experimental & clinical cancer research : CR*, 44(1), 242.

Wang B, et al. (2025) Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer. *Cell reports. Medicine*, 6(12), 102480.

Green WD, et al. (2025) Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment. *Immunity*, 58(7), 1725.

Frey HC, et al. (2025) A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum. *iScience*, 28(3), 112043.

Li A, et al. (2025) Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. *Developmental cell*, 60(14), 1974.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Oka T, et al. (2025) Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. *Cell reports*, 44(5), 115561.